Literature DB >> 9524078

Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brain.

J R Fike1, G T Gobbel, A H Mesiwala, H J Shin, M Nakagawa, K R Lamborn, T M Seilhan, P J Elliott.   

Abstract

The effects of an intravenous (i.v.) injection of the bradykinin analog RMP-7 (100 ng/kg) were assessed in normal dogs and dogs with focal, radiation-induced brain lesions. A dose of 20 Gy was delivered to a point 0.75 cm from a removable interstitial 125I source; parameters relating to blood flow and permeability were quantified using computed tomography 2-8 weeks after irradiation. Blood flow-related endpoints included regional cerebral blood flow (rCBF), mean transit time of blood and vascular volume, while endpoints related to permeability included blood-to-brain transfer constant (Ki), brain-to-blood transfer constant and plasma volume. In unirradiated brain, an i.v. bolus of RMP-7 administered through the left cephalic vein induced a rapid and transient hypotension and a statistically significant increase in vascular volume; no alterations in any parameter related to permeability were observed. After irradiation, changes in rCBF after RMP-7 depended upon time after exposure, effects presumably due to changing morphology in the irradiated tissues. In the radiation lesions, significant increases in Ki were observed 5 minutes after injection of RMP-7, but those increases were not related to time after irradiation or alteration in blood flow-related parameters. Our results showed that RMP-7 selectively increased permeability in already damaged vasculature without affecting the extent or volume of radiation-induced vasogenic edema. These data suggest that RMP-7 may provide an effective means to enhance the delivery of compounds to an already compromised brain while not exacerbating the potential adverse effects of pre-existing vasogenic edema.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9524078     DOI: 10.1023/a:1005874206814

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  39 in total

1.  Measurement of regional cerebral blood flow using ultrafast computed tomography. Theoretical aspects.

Authors:  G T Gobbel; C E Cann; J R Fike
Journal:  Stroke       Date:  1991-06       Impact factor: 7.914

2.  Radiation dose response of normal brain.

Authors:  J R Fike; C E Cann; K Turowski; R J Higgins; A S Chan; T L Phillips; R L Davis
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-01       Impact factor: 7.038

3.  In vitro plasma metabolism of RMP-7.

Authors:  J A Straub; A Akiyama; P Parmar
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

4.  Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis.

Authors:  L Axel
Journal:  Radiology       Date:  1980-12       Impact factor: 11.105

5.  Computed tomography analysis of the canine brain: effects of hemibrain X irradiation.

Authors:  J R Fike; C E Cann; R L Davis; J K Borcich; T L Phillips; L B Russell
Journal:  Radiat Res       Date:  1984-08       Impact factor: 2.841

6.  Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy.

Authors:  P J Elliott; N J Hayward; M R Huff; T L Nagle; K L Black; R T Bartus
Journal:  Exp Neurol       Date:  1996-10       Impact factor: 5.330

7.  Permeability of different experimental brain tumor models to horseradish peroxidase.

Authors:  D R Groothuis; J M Fischer; G Lapin; D D Bigner; N A Vick
Journal:  J Neuropathol Exp Neurol       Date:  1982-03       Impact factor: 3.685

8.  Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors.

Authors:  T Inamura; T Nomura; R T Bartus; K L Black
Journal:  J Neurosurg       Date:  1994-11       Impact factor: 5.115

9.  Cellular proliferation and infiltration following interstitial irradiation of normal dog brain is altered by an inhibitor of polyamine synthesis.

Authors:  J R Fike; G T Gobbel; D Chou; B P Wijnhoven; M Bellinzona; M Nakagawa; T M Seilhan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-15       Impact factor: 7.038

10.  Bradykinin selectively opens blood-tumor barrier in experimental brain tumors.

Authors:  T Inamura; K L Black
Journal:  J Cereb Blood Flow Metab       Date:  1994-09       Impact factor: 6.200

View more
  6 in total

1.  A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps.

Authors:  A Cenic; D G Nabavi; R A Craen; A W Gelb; T Y Lee
Journal:  AJNR Am J Neuroradiol       Date:  2000-03       Impact factor: 3.825

2.  Intravenous infusion of cereport increases uptake and efficacy of acyclovir in herpes simplex virus-infected rat brains.

Authors:  D J Bidanset; L Placidi; R Rybak; J Palmer; J P Sommadossi; E R Kern
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 3.  The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation.

Authors:  D F Emerich; R L Dean; C Osborn; R T Bartus
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 5.  Blood-brain barrier permeability following conventional photon radiotherapy - A systematic review and meta-analysis of clinical and preclinical studies.

Authors:  Elvin't Hart; Zelda Odé; Marc P P Derieppe; Lucianne Groenink; Martijn W Heymans; René Otten; Maarten H Lequin; Geert O R Janssens; Eelco W Hoving; Dannis G van Vuurden
Journal:  Clin Transl Radiat Oncol       Date:  2022-05-04

6.  Injectable SN-38-embedded Polymeric Microparticles Promote Antitumor Efficacy against Malignant Glioma in an Animal Model.

Authors:  Yuan-Yun Tseng; Tao-Chieh Yang; Shu-Mei Chen; Shun-Tai Yang; Ya-Ling Tang; Shih-Jung Liu
Journal:  Pharmaceutics       Date:  2020-05-24       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.